Epoetin alfa

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HIV Infections

Conditions

HIV Infections, Cytopenias

Trial Timeline

— → —

NCT ID

NCT00002022

About Epoetin alfa

Epoetin alfa is a pre-clinical stage product being developed by Johnson & Johnson for HIV Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00002022. Target conditions include HIV Infections, Cytopenias.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00270010	Phase 2	Completed	—	Aug 1, 1989	Anemia
NCT00266617	Phase 2	Completed	—	Jun 1, 1990	Anemia
NCT00002022	Pre-clinical	Completed	—	—	HIV Infections
NCT00269984	Phase 2	Completed	—	Jun 1, 1990	Anemia
NCT00269945	Phase 2	Completed	—	Jan 1, 1989	Anemia
NCT00270114	Phase 2/3	Completed	—	Mar 1, 1991	Anemia
NCT00446602	Phase 2	Withdrawn	—	Aug 1, 2009	Myelodysplastic Syndromes
NCT00270179	Phase 3	Completed	—	May 1, 1988	Anemia
NCT00269997	Phase 2	Completed	—	Jul 1, 1990	Anemia
NCT00270023	Phase 2/3	Completed	—	Nov 1, 1991	Blood Transfusion
NCT00270270	Phase 2	Completed	—	Jul 1, 1989	Acquired Immunodeficiency Syndrome
NCT00337935	Phase 2	Completed	Jul 1, 2006	Jul 1, 2009	Renal Failure , Chronic
NCT00306267	Phase 2	Terminated	Mar 1, 2006	May 1, 2007	Anemia
NCT00641589	Phase 1	Completed	Jan 1, 2006	Nov 1, 2006	Chronic Kidney Disease
NCT00246298	Phase 2	Terminated	Oct 1, 2005	Sep 1, 2006	Anemia
NCT00212875	Phase 2	Completed	Sep 1, 2005	Feb 1, 2007	Chronic Kidney Disease
NCT00236405	Phase 2	Terminated	Mar 1, 2005	Oct 1, 2005	Anemia
NCT00240734	Phase 2	Terminated	Mar 1, 2005	Sep 1, 2005	Anemia
NCT00210587	Phase 3	Completed	Feb 1, 2005	Dec 1, 2005	Anemia
NCT00236678	Phase 2	Terminated	Jul 1, 2004	Jan 1, 2006	Anemia

Competing Products

20 competing products in HIV Infections

See all competitors

Product	Company	Stage	Hype Score
AAVLP-HPV + Placebo	2A Pharma	Phase 1	25
VN-0200 + Placebo	Daiichi Sankyo	Phase 1	33
VN-0200	Daiichi Sankyo	Phase 2	52
Micafungin	Astellas Pharma	Pre-clinical	23
amphotericin B liposomal (Ambisome)	Astellas Pharma	Approved	85
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	23
Ciclosporin and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil + Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus	Astellas Pharma	Approved	85
Micafungin	Astellas Pharma	Pre-clinical	23
Micafungin	Astellas Pharma	Phase 1	33
Micafungin + Placebo	Astellas Pharma	Phase 3	77
Cefiderocol + Standard of Care	Shionogi	Phase 2	52
Dolutegravir + Rlipivirine + GSK1265744	Shionogi	Phase 1	33
Xeruborbactam Oral Prodrug + Ceftibuten	Shionogi	Phase 1	33
Cefiderocol + Standard of Care	Shionogi	Phase 2	52
Dolutegravir 50 mg twice daily + Dolutegravir placebo twice daily	Shionogi	Phase 3	77
Xeruborbactam Oral Prodrug + Ceftibuten + Xeruborbactam Oral Prodrug Placebo + Ceftibuten Placebo	Shionogi	Phase 1	33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granules	Shionogi	Phase 1	33
GW810781	Shionogi	Phase 2	52
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusion	Shionogi	Phase 1	33
Cefiderocol	Shionogi	Phase 2	52

Other Products from Johnson & Johnson

Fentanyl transdermal therapeutic systemApproved

Nicotine Gum + Nicotine PatchApproved

galantamineApproved

IbrutinibApproved

Paliperidone ERApproved